<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533087</url>
  </required_header>
  <id_info>
    <org_study_id>PACIFIC</org_study_id>
    <nct_id>NCT04533087</nct_id>
  </id_info>
  <brief_title>ImPACt on Invasive Fungal Infections by Immune Checkpoint Inhibition</brief_title>
  <acronym>PACIFIC</acronym>
  <official_title>ImPACt on Invasive Fungal Infections by Immune Checkpoint Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study aims to compare immune checkpoint expression in blood samples from&#xD;
      patients with invasive fungal infections (IFI) against healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participating sites will screen patients with invasive aspergillosis for eligibility. The&#xD;
      investigators will enroll patients with aspergillosis and healthy controls. Patients will be&#xD;
      informed by study personnel. Samples for imune phenotyping will be obtained within 7 days&#xD;
      after diagnosis of IFI. A bronchoalveolar lavage (BAL) biopsy is taken at initial diagnostic&#xD;
      bronchoscopy or other biopsy during surgical debridement whenever applicable and feasible.&#xD;
&#xD;
      The following data items will be collected: Patient characteristics, details on invasive&#xD;
      fungal infection (IFI), underlying disease, outcome after 90 days (response, remission,&#xD;
      progress, death). All collected data will be interpreted at the end of the study. All&#xD;
      patients must agree to participate and sign the informed consent form.&#xD;
&#xD;
      The primary objective is to compare immune checkpoint expression in blood samples from&#xD;
      patients with IFI against healthy controls. Exploratively, lymphocytic immune phenotypes in&#xD;
      BAL or other biopsy samples from patients with IFI will be assessed. Further, cytotoxic T&#xD;
      cell responses in blood samples from patients with IFI shall be investigated and the level of&#xD;
      immune checkpoint expression correlated with mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of immune checkpoint expression levels in blood samples from patients with IFI and healthy controls by flowcytometry</measure>
    <time_frame>3 years</time_frame>
    <description>To compare immune checkpoint expression in blood samples from patients with IFI against healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of lymphocytic immune phenotypes in BAL and other biopsy samples by flowcytometry</measure>
    <time_frame>3 years</time_frame>
    <description>To assess lymphocytic immune phenotypes in BAL and other biopsy samples from patients with IFI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of cytotoxic T cell responses in blood samples from patients with IFI by ELISA</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of T cell response on lymphocytes from peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of survival at day 30 and 90 and immune checkpoint expression levels</measure>
    <time_frame>4 years</time_frame>
    <description>To correlate the level of immune checkpoint expression with mortality.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Invasive Fungal Infections</condition>
  <arm_group>
    <arm_group_label>Candida blood stream infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspergillosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rare mold infections</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Aspergillosis</arm_group_label>
    <arm_group_label>Candida blood stream infection</arm_group_label>
    <arm_group_label>Rare mold infections</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood and biopsy (e.g. BAL)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with IFI and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Proven or probable, incl. PCR, positive IFI along 2019 EORTC/MSG criteria&#xD;
&#xD;
          -  Signed ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sibykke C Mellinghoff, Dr.</last_name>
    <phone>+4915901029684</phone>
    <email>sibylle.mellinghoff@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Arenz</last_name>
      <phone>+49-221-478 6494</phone>
      <email>dorothee.arenz@zks-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Oliver A. Cornely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Sibylle C Mellinghoff</investigator_full_name>
    <investigator_title>Resident physician and research affiliate</investigator_title>
  </responsible_party>
  <keyword>immune checkpoint</keyword>
  <keyword>invasive fungal infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

